{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"CRISPR Therapeutics AG"},"Symbol":{"label":"Symbol","value":"CRSP"},"Address":{"label":"Address","value":"BAARERSTRASSE 14, ZUG, CH-6300, Switzerland"},"Phone":{"label":"Phone","value":"+41 415613277"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes."},"CompanyUrl":{"label":"Company Url","value":"https://www.crisprtx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Jonathan Alexander Terrett","title":"Head-Research"},{"name":"Julianne Bruno","title":"Chief Operating Officer"},{"name":"Naimish Patel","title":"Chief Medical Officer"},{"name":"Samarth Kulkarni","title":"Chairman & Chief Executive Officer"},{"name":"Stephen R. Kennedy","title":"Head-Technical Operations"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}